The risk for anemia with targeted therapies for solid tumors

Related Experiment Video

Updated: May 22, 2026

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Sandro Barni1, Mary Cabiddu, Paolo Guarneri

  • 1Oncology Department, Medical Oncology Unit, Azienda Ospedaliera Treviglio, Italy.

The Oncologist
|April 26, 2012
PubMed
Abstract

Insights

Targeted therapies in cancer treatment increase anemia risk, particularly biological agents and tyrosine kinase inhibitors. Erythropoiesis-stimulating agents are not recommended for use without chemotherapy alongside targeted therapies.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Anemia is a frequent complication in cancer patients.
  • The specific risks of anemia associated with targeted cancer therapies remain largely uncharacterized.

Purpose of the Study:

  • To determine the incidence and relative risk of anemia in patients with solid tumors treated with targeted therapies.
  • To compare anemia risk between targeted therapy regimens and standard treatments.

Main Methods:

  • A meta-analysis of randomized controlled trials involving patients with solid tumors was conducted.
  • Targeted therapies (alone or in combination) were compared against standard therapy alone.
  • Incidence and relative risk (RR) for anemia events were calculated for 24,310 patients.

Main Results:

  • Targeted therapies increased the risk of all grades of anemia by 7% compared to standard treatment.
  • Biological therapies alone, but not in combination with chemotherapy, showed a higher RR for all grades (44%) and grades 1-2 (38.9%) anemia.
  • Significant anemia risk was noted for erlotinib, trastuzumab, and sunitinib, while bevacizumab showed a lower risk. Tyrosine kinase inhibitors (RR 1.33) and anti-EGFR (RR 1.24) agents increased risk.

Conclusions:

  • Grade 1-2 anemia is common with biological agents, especially small-molecule tyrosine kinase inhibitors (e.g., gefitinib, erlotinib) in breast and lung cancers.
  • Bevacizumab demonstrated a reduced risk of anemia.
  • Erythropoiesis-stimulating agents are not approved for use with targeted therapies without concurrent chemotherapy, and supportive care is the recommended approach.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...